“Using genomics to identify or define patients at risk for oral mucositis is close to becoming a clinically actionable reality,” Sonis tells Oncology Nurse Advisor. “Identification of genes associated with drug metabolism has been available for some time and has focused on genes controlling the enzymes for mucotoxic agents [such as] 5-FU and methotrexate. And while genetic defects associated with drug metabolism are relatively rare, their identification and association with toxicity risk served as proof-of-concept.”
“Utilization of sophisticated analytics that recognize that genes are ‘team players’ has enabled genomic risk prediction for mucositis among patients receiving conditioning regimens prior to stem cell transplant and [patients] receiving conventional chemotherapy regimens,” Sonis adds. Toxicity risk prediction should also be applied to patients whose treatment plan includes radiation therapy, he explained.
Oncology nurses bear the brunt of symptom prevention and management, Sonis notes. “They are generally the health care providers with the most contact with patients. Consequently, oncology nurses are often best placed to convey to patients the importance of oral health in the context of overall well-being and to teach, assess, and monitor all aspects of oral health during treatment. Importantly, by recognizing abnormalities in the clinical appearance of the mouth or in symptom complexes associated with it, oncology nurses can catalyze aggressive intervention to prevent small problems from becoming disasters.”
Bryant Furlow is a medical journalist based in Albuquerque, New Mexico.
1. Lalla RV, Saunders DP, Peterson DE. Chemotherapy or radiation-induced oral mucositis. Dent Clin North Am. 2014;58(2):341-349. doi:10.1016/j.cden.2013.12.005.
2. Jensen SB, Peterson DE. Oral mucosal injury caused by cancer therapies: current management and new frontiers in research. J Oral Pathol Med. 2014;43(2):81-90. doi:10.1111/jop.12135.
3. Lalla RV, Bowen J, Barasch A, et al; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453-1461. doi:10.1002/cncr.28592.
4. Eilers J, Million R. Clinical update: prevention and management of oral mucositis in patients with cancer. Semin Oncol Nurs. 2011;27(4):e1-e16. doi:10.1016/j.soncn.2011.08.001.
5. Villa A, Sonis ST. Mucositis: pathobiology and management. Curr Opin Oncol. 2015;27(3):159-164. doi:10.1097.CCO.0000000000000180.
6. Holt ER, Potts T, Toon R, Yoder M. Oral manifestations of cancer therapy: advice for the medical team. J Nurse Pract. 2015;11(2):253-257.
7. Seiler S, Kosse J, Loibl S, Jackisch C. Adverse event management of oral mucositis in patients with breast cancer. Breast Care (Basel). 2014;9(4):232-237. doi:10.1159/000366246.
8. Allison RR, Ambrad A, Arshoun Y, et al. Multi-institutional, randomized, double-blind, placebo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. Cancer. 2014;120(9):1433-1440.
9. Lalla RV, Choquette LE, Curley KF, et al. Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol. 2014;50(11):1098-1103.
10. Antunes HS, Herchenhorn D, Small IA, et al. Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation. Radiother Oncol. 2013;109(2):297-302. doi:10.1016/j.radonc.2013.08.010.
11. Nicolatou-Galitis O, Sarri T, Bowen J, et al; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(11):3179-3189. doi:10.1007/s00520-013-1847-y.